CSIMarket
 


Molecular Templates inc   (MTEM)
Other Ticker:  
 
 

MTEM's Income from Cont. Operations Growth by Quarter and Year

Molecular Templates Inc 's Income from Cont. Operations results by quarter and year




MTEM Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 24.42 15.60 31.23
III Quarter September 4.15 21.61 26.78 22.02
II Quarter June 22.05 10.24 28.45 15.88
I Quarter March 24.64 30.39 23.23 38.22
FY   50.84 86.66 94.06 107.35



MTEM Income from Cont. Operations third quarter 2023 Y/Y Growth Comment
Molecular Templates Inc reported drop in Income from Cont. Operations in the third quarter 2023 by -80.78% to $ 4.15 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Molecular Templates Inc 's Income from Cont. Operations compares unfavorably to the Company's average Income from Cont. Operations doubling of 103.55%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 32 other companies have achieved higher Income from Cont. Operations growth. While Molecular Templates Inc ' s Income from Cont. Operations meltdown of -80.78% ranks overall at the positon no. 2012 in the third quarter 2023.




MTEM Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - 56.54 % -50.05 % 241.31 %
III Quarter September -80.78 % -19.31 % 21.62 % 256.89 %
II Quarter June 115.33 % -64.01 % 79.16 % 139.52 %
I Quarter March -18.92 % 30.82 % -39.22 % 629.39 %
FY   - -7.87 % -12.38 % 294.81 %

Financial Statements
Molecular Templates Inc 's third quarter 2023 Income from Cont. Operations $ 4.15 millions MTEM's Income Statement
Molecular Templates Inc 's third quarter 2022 Income from Cont. Operations $ 21.61 millions Quarterly MTEM's Income Statement
New: More MTEM's historic Income from Cont. Operations Growth >>


MTEM Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 13 % -41.75 % 41.83 %
III Quarter September -81.17 % 111.04 % -5.87 % 38.66 %
II Quarter June -10.51 % -66.3 % 22.47 % -58.45 %
I Quarter March 0.9 % 94.81 % -25.62 % 317.7 %
FY (Year on Year)   - -7.87 % -12.38 % 294.81 %




Income from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #33
Healthcare Sector #125
Overall #2012

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
746.72 % 103.55 % -83.14 %
(Jun 30 2018)   (Sep 30 2023)
Income from Cont. Operations third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #33
Healthcare Sector #125
Overall #2012
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
746.72 % 103.55 % -83.14 %
(Jun 30 2018)   (Sep 30 2023)

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Molecular Templates Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
317.56 % 22.22 % -66.29 %
(Sep 30 2019)  


MTEM's III. Quarter Q/Q Income from Cont. Operations Comment
In the III. Quarter 2023 Molecular Templates Inc reported fall in Income from Cont. Operations from the previous quarter by -81.17% to $ 4.15 millions, from $ 22.05 millions declared in the previous reporting period.

Even cyclical circumstance that usually fuel III. Quarter 2023 performance, could not rescue the III. Quarter for the Molecular Templates inc , Stephanie H. Clark, Healthcare sector insider said and continued that average quarter on quarter Income from Cont. Operations growth is at 22.22% for Molecular Templates Inc .

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Income from Cont. Operations quarter on quarter growth. While Molecular Templates Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 1913.


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #120
Overall #1913
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #120
Overall #1913
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
317.56 % 22.22 % -66.29 %
(Sep 30 2019)  


MTEM's III. Quarter Q/Q Income from Cont. Operations Comment
In the III. Quarter 2023 Molecular Templates Inc disclosed fall in Income from Cont. Operations sequentially by -81.17% to $ 4.15 millions, from $ 22.05 millions declared in the previous reporting period.

Some seasonal influence have not salvage the III. Quarter for the Molecular Templates inc , Stephanie H. Clark, Healthcare sector insider pointed out, she mentioned certan skepticism towards Molecular Templates Inc 's perspective, she identified new difficulties ahead for Molecular Templates Inc .

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Income from Cont. Operations quarter on quarter growth. While Molecular Templates Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 1913.


Molecular Templates Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ 75.26 $ 92.72 $ 92.72 $ 92.72 $ 80.91
Y / Y Income from Cont. Operations Growth (TTM) -3.32 % 11.7 % 11.7 % 11.7 % -20.06 %
Year on Year Income from Cont. Operations Growth Overall Ranking # 1243 # 0 # 0 # 1439 # 1181
Seqeuential Income from Cont. Operations Change (TTM) -18.83 % 14.59 % 14.59 % 14.59 % -6.63 %
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # 1141 # 0 # 0 # 1403 # 1396




Cumulative Income from Cont. Operations growth Comment
For the 12 months ended Sep 30 2023 Molecular Templates Inc reported a decrease in Income from Cont. Operations by -3.32% year on year, to $75 millions, compare to the 11.7% growth at Dec 31 2022.

In the Healthcare sector 82 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Income from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 0 to 1243.

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
294.67 %
-96.17 %
-2339 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 15
Healthcare Sector # 83
Overall # 1243

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
294.67 %
-96.17 %
-2339 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 78
S&P 500 # 1141
Cumulative Income from Cont. Operations growth Comment
For the 12 months ended Sep 30 2023 Molecular Templates Inc reported a decrease in Income from Cont. Operations by -3.32% year on year, to $75 millions, compare to the 11.7% growth at Dec 31 2022.

In the Healthcare sector 82 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Income from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 0 to 1243.

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
294.67 %
-96.17 %
-2339 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 15
Healthcare Sector # 83
Overall # 1243

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
294.67 %
-96.17 %
-2339 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 78
S&P 500 # 1141




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
MTEM's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for MTEM's Competitors
Income from Cont. Operations Growth for Molecular Templates Inc 's Suppliers
Income from Cont. Operations Growth for MTEM's Customers

You may also want to know
MTEM's Annual Growth Rates MTEM's Profitability Ratios MTEM's Asset Turnover Ratio MTEM's Dividend Growth
MTEM's Roe MTEM's Valuation Ratios MTEM's Financial Strength Ratios MTEM's Dividend Payout Ratio
MTEM's Roa MTEM's Inventory Turnover Ratio MTEM's Growth Rates MTEM's Dividend Comparisons



Companies with similar Income from Cont. Operations decrease for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2023
Shockwave Medical Inc -0.05%$ -0.049 millions
Xeris Biopharma Holdings Inc -0.29%$ -0.295 millions
Tenet Healthcare Corp-0.75%$ -0.746 millions
U S Physical Therapy Inc-4.67%$ -4.672 millions
Universal Health Services Inc -4.98%$ -4.979 millions
National Research Corporation-5.09%$ -5.086 millions
Hca Healthcare Inc -5.13%$ -5.134 millions
Viatris Inc -6.41%$ -6.407 millions
Pacific Health Care Organization Inc -6.71%$ -6.710 millions
Mettler toledo International Inc -8.60%$ -8.598 millions
Corcept Therapeutics Inc-9.78%$ -9.777 millions
Charles River Laboratories International inc -9.83%$ -9.826 millions
Third Harmonic Bio Inc -10.51%$ -10.506 millions
The Pennant Group Inc -10.65%$ -10.653 millions
Henry Schein Inc-11.73%$ -11.728 millions
Quest Diagnostics Inc-14.13%$ -14.130 millions
Carlisle Companies Incorporated-15.01%$ -15.008 millions
Stryker Corp-15.20%$ -15.196 millions
Zimmer Biomet Holdings Inc -16.12%$ -16.117 millions
Amgen Inc -19.27%$ -19.272 millions
Entera Bio Ltd -22.43%$ -22.432 millions
Regeneron Pharmaceuticals Inc -23.40%$ -23.402 millions
Pediatrix Medical Group Inc -25.75%$ -25.746 millions
Zynex inc -26.25%$ -26.247 millions
Evofem Biosciences Inc -26.26%$ -26.256 millions
Tenax Therapeutics Inc -32.39%$ -32.386 millions
Avantor Inc -35.09%$ -35.090 millions
Ufp Technologies Inc -40.15%$ -40.154 millions
Bio techne Corp-43.17%$ -43.173 millions
Royalty Pharma Plc-44.61%$ -44.615 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com